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Abstract. The application of the beta particle-emitting
nuclide 67Cu in radioimmunotherapy is reviewed. The
production of the nuclide is outlined, and different pro-
duction modes are discussed with an emphasis on cyclo-
tron production. A short survey of copper chelators cur-
rently used for antibody labelling and their impact on the
pharmacokinetics of 67Cu-labelled immunoconjugates is
provided. Protocols for antibody labelling with 67Cu as
well as quality control procedures for 67Cu-labelled anti-
bodies are described. Preclinical data on the biological
properties of 67Cu-labelled immunoconjugates are re-
ported and discussed. 67Cu-labelled antibodies show
higher and more persistent tumour uptake than their ra-
dioiodinated counterparts due to accumulation of la-
belled metabolites in tumour cells. Biodistribution of
67Cu-labelled antibody fragments has been improved by
selection of negatively charged chelators and peptide
linkers. Pharmacokinetic analysis of the accumulated
dose in tumour and critical organs such as the kidney and
liver indicates that, despite this improvement, intact
67Cu-labelled antibodies achieve higher tumour uptake
and better therapeutic ratios than 67Cu-labelled antibody
fragments and that they are at present the logical choice
for clinical studies. Clinical studies using 67Cu-labelled
antibodies in lymphoma, colon carcinoma and bladder
cancer patients are reviewed. Some of the advantages
over radioiodinated antibodies found in the preclinical
work, such as higher tumour uptake and better tu-
mour/blood ratios, have also been found with systemic
application in lymphoma and colon carcinoma. However,
in both lymphoma and colon carcinoma patients, the ra-
diation dose to the liver has been found to be higher
from 67Cu- than from 131I-labelled antibodies. The intra-
vesical application of 67Cu-labelled antibody has been
shown to be a promising approach for targetting cytotox-
ic radiation to superficial bladder tumours, without de-
tectable systemic absorption. Given the favourable prop-
erties of 67Cu-labelled antibodies, it is the reliable avail-
ability of the 67Cu nuclide which is the limiting factor for
their more widespread evaluation in radioimmunothera-
py trials.
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Introduction
Monoclonal antibodies have been recognised as highly
selective agents for systemic nuclide therapy for a long
time. Due to the persistent efforts to improve their effica-
cy, a clinical impact of radioimmunotherapy (RAIT) is
already apparent in the treatment of haematological ma-
lignancies. Especially in non-Hodgkin’s lymphoma, no-
table clinical responses have been observed in patients
with relapsed, chemotherapy-resistant disease and vari-
ous radiolabelled antibodies are in phase I/II/III trials (as
reflected, for instance, in the increasing number of ab-
stracts on the subject at the EANM annual meetings). In
the management of solid tumours, RAIT may be more
effective in the treatment of residual disease and/or adju-
vant settings, and especially locoregional applications of
radiolabelled antibodies appear to be a favourable mo-
dality. 131I and 90Y are now the most widely used beta
particle-emitting nuclides in clinical RAIT. The high en-
ergy of 90Y and its long particle range make it suitable
for irradiating large tumour masses. For the treatment of
small, distant metastases, a variety of beta particle-emit-
ting nuclides covering a range of energies and thus pene-
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tration ranges would be of interest, because then the pen-
etration range of the nuclide could be matched to the tu-
mour size [1, 2]. Also a choice amongst nuclides with
different half-lives would be useful, to permit matching
of the physical half-life of the nuclide to the different
pharmacokinetics of intact antibodies and antibody frag-
ments. Apart from the physical properties of the nuclide,
its availability and the existence of simple and efficient
radiolabelling methods are important considerations. On
the biological side, the fate of the nuclide after antibody
metabolism in vivo plays an important role and is also
dependent on the nuclide used and the labelling chemis-
try involved.
The physical properties of the 67Cu nuclide are very
well suited for its application in RAIT and are summari-
sed in Table 1. 67Cu is a beta particle-emitting nuclide
with β– emissions distributed between 577 and 395 keV,
resulting in a mean energy of 141 keV, similar to the
mean β energy of 131I (180 keV). These therapeutic β–
emissions, with a mean range of 0.2 mm, are very appro-
priate for the treatment of small tumours up to 5 mm in
diameter. 67Cu also emits γ-radiation in the range
91–184 keV (49% abundance), an energy range which is
particularly suitable for pretherapy diagnostic imaging
with a gamma camera. In contrast to the high level
(>90%) of penetrating γ-radiation associated with the 131I
nuclide, which adds to the whole-body dose of the pa-
tient and to the radiation burden of the hospital staff, the
lower abundance and energy of the γ emissions from
67Cu represent a distinct advantage. Given the relatively
slow pharmacokinetics of intact antibody molecules, the
half-life of the 67Cu nuclide of 2.58 days is long enough
to permit accumulation of antibody at the tumour site.
On the other hand, its half-life is not as long as that of
131I (T1/2=8.04 days), and 67Cu thus provides a higher
dose rate to the tumour.
This review will cover preclinical and clinical studies
performed with 67Cu-labelled antibodies, which all indi-
cate the great potential of 67Cu for RAIT. Results ob-
tained so far indicate that a commitment to producing
this interesting nuclide for clinical studies is a worth-
while endeavour. 64Cu, a positron-emitting nuclide used
for positron emission tomography (PET) imaging will
not be treated comprehensively in this review, but stud-
ies with 64Cu-labelled antibody or peptide conjugates
will be mentioned in some instances, when pertinent to
nuclide therapy using the 67Cu sister nuclide.
Production of 67Cu
As indicated in Table 1, 67Cu can be produced by bom-
barding 67Zn with neutrons in high flux reactors [3], or
with cyclotrons by irradiating natZn or enriched 68Zn with
protons [4, 5]. These are the most commonly used proce-
dures; other less practicable methods such as irradiation
by α-particles are listed in, for instance [4]. As reactors
are getting to be rare (at least in Europe), production
routes from cyclotrons are of particular interest. In the
case of 67Cu production using cyclotrons, the yield from
the (p, 2p) nuclear reactions is relatively low, and effi-
cient separation procedures to remove the contaminating
nuclides have had to be developed [4]. The main con-
taminants are 62Zn, 67Ga, 65Zn, 55Co, 58Co and 57Ni, all
of which can be removed by sequential steps of ion ex-
change chromatography. 67Cu produced via this no-carri-
er-added production is, however, not carrier free, 
owing to the difficulty of removing trace contaminants
of Cu in the Zn target, apparatus and solutions. Current
67Cu productions have a specific activity of about
37–185 MBq/µg [4, 5] and as a consequence less than
1% of the copper atoms are radioactive. Because the
yield of the nuclear (p, 2p) reaction for 64Cu is higher
than for 67Cu, 64Cu is produced simultaneously with
67Cu and remains present in 67Cu preparations for sever-
al days, despite its shorter half-life (T1/2=12.7 h).
67Cu has been produced in the United States with
high-energy accelerators at Brookhaven and Los Alamos
National Laboratories but is not provided on a routine
basis by these institutions. Since 1994, the Center for
Radiopharmaceutical Science at the Paul Scherrer Insti-
tute (PSI) in Switzerland has produced 67Cu for its own
use with a 72-MeV accelerator. An increase in 67Cu pro-
duction at PSI from the present 3.7 GBq to a projected
17 GBq is currently being affected by use of enriched
68Zn as the target material. Figure 1 shows the yield of
67Cu using natZn, 68Zn and 70Zn targets and a proton
beam with energies up to 70 MeV. Results indicate that
using 68Zn targets instead of natZn leads to a 4.5-fold in-
crease in 67Cu production in the energy range between
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Table 1. Physical properties
and more frequently used pro-
duction modes for 67Cu/64Cu
Nuclide T1/2 (h) Decay mode Eβ (keV, %) Eγ (keV, %) Production mode
67Cu 61.9 β– (100%) 395 (51%) 91 (6%) Cyclotron natZn (p, 2p)
484 (28%) 93 (35%) Cyclotron 68Zn (p, 2p)
577 (20%) 185 (45%) Reactor natZn (n, p)
300 (0.6%)
64Cu 12.7 β– (39.6%) 573 (40%) 511 (39%) Reactor
EC (45.0%) 1,346 (0.6%) Cyclotron
β+ (19.3%)
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Fig. 1. Yields (on a log scale) of 67Cu activity produced by proton
irradiation of Zn targets. Compared with the irradiation of natural
Zn targets (squares), use of enriched 68Zn (diamonds) gives a 4.5-
fold increase in 67Cu in the energy range between 45 and 67 MeV
and the use of enriched 70Zn (triangles) gives a 10- to 20-fold in-
crease in 67Cu in the low energy range between 20 and 30 MeV.
(From Schwarzbach et al. [6])
Fig. 2A–F. Structures of selected macrocyclic bifunctional chel-
ators used for 67Cu labelling of antibodies. A 6-[p-(bromoacetami-
do)benzyl]-TETA (BAT); B 3-(L-p-isocyanato-phenylalanine)-
DOTA (NCS-DOTA); C 1-(L-p-isocyanato-phenylalanine)-DO3A
(NCS-DO3A); D DOTA-triglycyl-L-p-isocyanato-phenylalanine
(NCS-R1-DOTA; E 1-(p-phenyl-N-hydroxysuccinimide)-CPTA
(NHS-CPTA); F CPTA-triglycyl-L-p-isocyanato-phenylalanine
(NCS-R1-CPTA)
40 and 70 MeV. In a narrow low-energy range between
20 and 30 MeV, irradiation of a 70Zn target would in-
crease yields of 67Cu 10- to 20-fold. The high cost of the
70Zn target makes its use impractical, however. Using a
68Zn target, which can be recycled, will allow the pro-
duction of about 17 GBq of 67Cu, which is sufficient for
achieving several therapeutic doses of antibody, envisag-
ing 2.2 GBq (60 mCi) as the highest dose level [6].
When higher energy proton beams and higher beam
currents are available, about 10 times more 67Cu will be
produced per mass unit of Zn. Thus, sufficient amounts
of 67Cu for RAIT trials can be produced by cyclotrons, if
either enriched Zn targets are used or a high-energy pro-
ton beam is available.
Copper chelates and 67Cu labelling 
of antibodies
One of the advantages of the copper nuclides compared
with other radiometals of interest for nuclide therapy
consists in the availability of excellent chelating agents
(Fig. 2). The prototype is the macrocyclic chelator
1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic
acid (TETA, Fig. 2A) developed for copper labelling by
the Meares group [7, 8] a bifunctional carboxylated cy-
clam-14 derivative which complexes copper selectively
and rapidly at ambient temperature [9, 10]. This property
permits convenient postconjugation labelling protocols
at temperatures maintaining protein function.
The pharmacokinetics of antibodies are characterised
by long biological half-lives in the blood and in the tu-
mour, and the copper nuclide has to remain stably encap-
sulated in the chelator. Kinetic inertness of copper com-
plexes is the determining factor for release of radiocop-
per from antibody conjugates. The TETA ligand, as well
as a number of other 4 N macrocycles [11, 12, 13] de-
picted in Fig. 2, forms copper (II) complexes of high
thermodynamic stability, which also exhibit high kinetic
stability under physiological conditions [10]; this is one
of the reasons for the excellent tumour targetting ability
of 67Cu-labelled antibodies. Positioning of the side chain
on the TETA macrocycle influences the kinetic stability
of the copper complex, with the 6-position of the side
chain providing higher stability in human serum than the
macrocycle with the side chain at the 2-position [10].
There are different possibilities to attach the linkage
group to the DOTA chelate: on the macrocycle via a
C–C bond (Fig. 2B) or on the acetate chelating arm via a
C–N bond (“DO3A”) (Fig. 2C). Both ligands form very
stable copper complexes but the DO3A ligand has been
used more, possibly because of the more convenient syn-
thesis [12, 14]. Intact antibodies are metabolised in the
liver where copper binding proteins such as ceruloplas-
min and superoxide dismutase are present in high con-
centrations. Despite the high kinetic stability of the
TETA copper complex, transchelation of Cu from 
the complex to these proteins in the liver has been ob-
served in vivo with 67Cu-TETA-labelled antibodies and 
64Cu-TETA-labelled octreotide [15, 16]. We have also
observed that 67Cu-DO3A-labelled antibodies and anti-
body fragments are characterised by relatively high lev-
els of activity in the liver. Ongoing interest therefore ex-
ists in designing copper chelates of even higher in vivo
stability. Recently, cross-bridged cyclam ligands were
synthesised with increased reduction potential in order to
lessen the electrochemical reduction of Cu(II) to Cu(I),
which is believed to affect dissociation of copper from
the complex [17, 18]. However, complexation of copper
with these ligands requires elevated temperatures (75°C),
which is not optimal for postconjugation labelling of
proteins, and these ligands therefore may be more suit-
able for peptide labelling. The neutral tetra-aza macrocy-
cle CPTA (Fig. 2E) exhibits a particularly high stability
towards acid-promoted dissociation of copper from the
complex [12, 19], which is relevant in the acidic envi-
ronment of lysosomes in antibody-metabolising tissues
such as the liver.
Besides the in vivo stability of the used copper com-
plexes, their charge and lipophilicity also have an impor-
tant impact on the biodistribution of 67Cu-labelled im-
munoconjugates. Macrocyclic copper complexes bearing
different charges and exhibiting different degrees of lipo-
philicity, such as 67Cu-CPTA, -TETA or -DO3A com-
plexes, lead to distinct differences in biodistribution
when used for labelling of antibody fragments. The
chelates (TETA, DOTA, DO3A) with carboxylic groups
(pKa values in the range 2–5) attached to the nitrogen
donor atoms are very hydrophilic. Indeed, clearance of
radioactivity from the kidneys was found to be much
faster in the case of antibody fragments substituted with
negatively charged hydrophilic copper complexes [20,
21].
Bifunctional copper chelators contain, in addition to
the metal chelating unit, a linkage and conjugation group
for attachment to the tumour-seeking moiety. Conjuga-
tion of chelates to antibodies is performed via electro-
philic conjugation groups (activated esters), attached to a
linker, which can be a phenyl group or a short peptide in
addition to the phenyl group. Figure 2 shows the most
frequently used conjugation groups: bromoacetamide
(BA) attached to the TETA ligand (BAT, Fig. 2A), iso-
thiocyanate (NCS) attached to DOTA or DO3A ligands
(Fig. 2B, C, D) and N-hydroxysuccinimide (NHS) at-
tached to the CPTA chelate (Fig. 2E) [7, 22]. In the case
of BA, linkage is to sulfhydryl groups introduced into
the protein by a first coupling reaction of lysine residues
with iminothiolane (IT). In the case of NCS and NHS,
coupling is directly to the primary amine groups of ly-
sine residues. A triglycine linker between the DO3A
chelator and the coupling group to the protein (Fig. 2D,
F) was found to further improve the biodistribution of
67Cu-DO3A- and 67Cu-CPTA-labelled antibody frag-
ments [22, 23]. The extent of conjugation of chelates to
the antibody has to be optimised in every case in order to
ensure that immunoreactivity is retained after conjuga-
tion. It also has to be considered that even when no ef-
fect on immunoreactivity is observed, substituting the
protein with too large a number of ligands can lead to
significant changes in biodistribution and increased ac-
tivity in the liver [24]. Ligand-substituted antibodies can
be stored at 4°C prior to labelling with 67Cu.
67Cu labelling
Labelling with 67Cu is performed by incubation of sub-
stituted antibodies with 67Cu for 30 min at ambient tem-
perature. Excess and non-specifically bound copper is
complexed by addition of EDTA or an excess of the li-
gand used for labelling. Antibodies are then purified
over a gel filtration column. These mild labelling condi-
tions ensure that the immunoreactivity of the conjugates
is fully retained. The specific activity of 67Cu-labelled
immunoconjugates depends on the amount of chelates
bound per antibody molecule, which is limited by dam-
age to immunoreactivity and increases in normal tissue
(mostly liver) uptake [24]. The specific activity of the
67Cu used for labelling also represents a limiting factor.
At present, specific activities of 67Cu-labelled immuno-
conjugates are in the range of 37 MBq (1 mCi)/mg. This
is sufficiently high for in vivo antibody targetting, but
currently many high-affinity receptor binding peptides
cannot be labelled with 67Cu to specific activities high
enough for in vivo receptor binding. It is expected that
higher labelling yields and higher specific activities will
be achieved by increasing the 67Cu production to
>50 GBq, because the amount of contamination by inac-
tive copper present during the radiochemical isolation of
67Cu from the irradiated target remains unchanged, re-
sulting in an increased ratio of 67Cu to Cu. When 67Cu
with higher specific activity becomes accessible, it may
also prove possible to label tumour targetting peptides to
sufficiently high specific activities.
Quality control of 67Cu-labelled antibodies
Assessment of radiochemical purity and radionuclide
identity
The fraction of radiocopper bound to antibody (radio-
chemical purity) can be determined by thin-layer chro-
matography (TLC) using silica gel and a solvent consist-
ing of 10% ammonium acetate in H2O and methanol
(vol/vol =1/1) [9]. Unchelated copper readily binds to
protein and TLC solid phase; therefore EDTA solution is
added to a final concentration of 5 mM to the antibody
solution. After copper labelling and purification of la-
belled antibody by gel filtration FPLC chromatography,
>95% of the radiocopper is associated with antibody.
824
European Journal of Nuclear Medicine Vol. 29, No. 6, June 2002
Radionuclide identity can be assessed by gamma-
spectroscopy. We found that in antibody preparations la-
belled via the CPTA chelator, the amount of the main
contaminants, 67Ga (T1/2 78.3 h) and 57Ni (T1/2 36 h), is
below 5%, and there is less than 0.1% 65Zn (T1/2 244.3
days) in the 67Cu-labelled antibody preparations.
64Cu is present in the 67Cu-labelled antibody prepara-
tion, the amount depending on the time that has elapsed
since 67Cu production (end of bombardment, EOB). An
antibody preparation delivered 72 h after EOB with an
activity of 37 MBq of 67Cu contains an additional
37 MBq of 64Cu. Because of its shorter half-life, the ac-
tivity due to 64Cu declines more rapidly than that due to
67Cu. Because the photons emitted by 64Cu contribute to
the radiation burden of the patient and have an impact on
image resolution, it is of interest to assess the amount
that will be present at the time of application by mea-
surement with a gamma-spectrometer or use of a cali-
brated ionisation chamber [25].
Assessment of antibody aggregates 
and of immunoreactivity
The purification of the 67Cu-labelled antibody by FPLC
gel filtration chromatography assures optimal quality,
because it not only separates the unchelated copper but
also removes antibody aggregates which can lead to un-
wanted accumulation of radioactivity in the liver or
spleen. Antibody aggregates are usually not generated by
the labelling procedure, but are frequently present to a
variable extent in the antibody solutions used for label-
ling. Immunoreactivity of the labelled preparation is test-
ed by binding assays. If the antigen is not available in
pure form, binding to antigen-expressing tumour cells
(which can be fixed onto microtitre plates and stored in
this form) is measured and evaluated according to the
method reported by Lindmo et al. [26]. In the case of
67Cu-C595 anti-mucin antibody, where the epitope is
known, binding to the peptide epitope attached to a solid
phase support can be used [27].
Biological behaviour of 67Cu-labelled antibodies
Comparison with 131I-labelled antibodies
When a number of different 67Cu-labelled antibodies
were assessed in nude mice bearing human tumour xeno-
grafts, it was found that they consistently showed higher
tumour uptake and a longer residence time of radioactiv-
ity at the tumour than their radioiodinated counterparts
[19, 20, 28, 29]. Together with the low levels of radioac-
tivity observed in normal tissues, the data indicated that
67Cu-labelled antibodies are superior tumour targetting
vehicles. Accordingly, the antitumour activity of 67Cu-
labelled Lym-1 anti-lymphoma antibody in mice with
human Burkitt’s lymphoma was found to be higher than
that of the corresponding 131I-labelled Lym-1 [30]. One
of the reasons for these effects lies in the moderate sta-
bility of radioiodinated proteins towards enzymatic deio-
dination. In vivo the stability of radioiodinated antibod-
ies, which are labelled on tyrosine residues, is affected
by relatively rapid deiodination followed by fast elimina-
tion of iodotyrosine from tumour and normal tissues.
The development of iodination methods providing deio-
dinase-resistant linkage of iodine to proteins has only
partially overcome this problem [31, 32]. In the case of
radiocopper-labelled antibodies, metabolism proceeds by
digestion with proteases and peptidases and the terminal
degradation product consists of lysine adducts of the
copper complexes used for antibody labelling [20, 21].
Clearance of radioactivity from normal tissues such as
the liver or the kidney depends on kinetic stability of the
copper complexes and the charge and lipophilicity of the
resulting metabolites. As already mentioned, despite the
high kinetic stability of macrocyclic copper complexes,
transchelation of Cu from the copper complex to copper-
binding proteins in the liver has been observed in vivo
with both 67Cu-TETA-labelled Lym-1 antibody [15] and
64Cu-TETA-labelled octreotide [16]. The antibody and
the peptide conjugate are both metabolised in the liver.
In the case of 64Cu-TETA-labelled octreotide, metabo-
lism was studied in rat liver and 20 h post injection 64Cu
was found to be predominantly associated with a 32-kDa
protein co-migrating with the copper-binding liver en-
zyme superoxide dismutase [16]. When 67Cu-2IT-BAT-
Lym-1 antibody was administered to patients, a small
fraction of 67Cu (about 2.8%) was found to be slowly re-
cycled during metabolism and was detected bound to
ceruloplasmin [15, 33].
In the case of internalising immunoconjugates, 67Cu
has a particular advantage over 131I. It has been shown
that in the case of the anti-neuroblastoma antibody
chCE7, which is taken up into target tumour cells and
degraded in lysosomes [34], radioactivity from radioio-
dinated antibody is washed out from tumour cells,
whereas the terminal metabolite of 67Cu-CPTA-chCE7 is
retained intracellularly [35]. Consequently, 67Cu-labelled
internalising immunoconjugates show a longer residence
time in tumour, similar to that of conjugates with other
“residualising” nuclides such as 111In and 90Y [31, 36,
37], and should thus deliver higher tumour doses than
131I-labelled internalising antibodies.
Comparison of intact antibody and antibody fragments
The more rapid pharmacokinetics and better tumour pen-
etration of antibody fragments are potentially valuable
properties for applications in RAIT, and genetically engi-
neered antibody single chain fragments (scFv) as well as
enzymatically prepared Fab' and F(ab')2 fragments la-
belled with various radionuclides have been evaluated
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for their tumour targetting ability. In the case of the in-
ternalising chCE7 antibody, the tumour targetting ability
of 67Cu-labelled non-internalising monovalent scFv and
Fab' fragments has been compared with internalising di-
valent F(ab')2 fragments [38]. Table 2 summarises some
of this work, indicating a ninefold increase in tumour up-
take of 67Cu-CPTA-labelled F(ab')2 fragments compared
with 67Cu-CPTA-labelled Fab' fragments. Compared
with the moderate tumour uptake achieved with monova-
lent Fab' fragments, divalent internalising antibody frag-
ments combine high tumour uptake with rapid clearance
from the blood and therefore could potentially attain a
better therapeutic index than intact antibodies. However,
as indicated in Table 2, high levels of radioactivity in the
kidneys are observed with 67Cu-CPTA-labelled Fab' and
F(ab')2 antibody fragments, proteins which are metabo-
lised in the kidney, and the metabolite 67Cu-CPTA-Lys is
retained in the proximal tubule cells [20]. Similarly, high
retention of radioactivity in the kidneys was found with a
number of other antibody fragments, labelled with 67Cu
[28] and with the PET nuclide 64Cu [39]. Blockade of re-
nal uptake with lysine was found to reduce radioactivity
in the kidneys in the case of 67Cu-CPTA-labelled SEN7-
F(ab')2 fragments, but was not effective in reducing kid-
ney accumulation of radioactivity from 67Cu-CPTA-
mAb35 F(ab')2, indicating that it is not a generally appli-
cable solution to reduce radioactivity in the kidneys [40].
Another approach to reduce radioactivity in the kidney is
to use chelates bearing negative charges and to introduce
cleavable linkers between antibody fragments and Cu
chelates. We found that a triglycine linker (originally in-
troduced by Li and Meares [14]) improved clearance of
67Cu-CPTA-F(ab')2 from the kidney, possibly by leading
to a metabolite with a terminal Gly instead of a terminal
Lys residue, which is not taken up into proximal tubule
cells [22]. Data in Table 2 show that when the triglycine
linker was combined with the anionic DO3A chelate, the
F(ab)2 conjugate with the triglycine linkage group
showed about a sixfold reduction in radioactivity present
in the kidneys owing to the negative charge of the DO3A
chelate and, at the same time, significantly higher tu-
mour uptake, probably due to its slower pharmacokinet-
ics [22, 23]. Substantial improvement in the biodistribu-
tion of 67Cu-labelled F(ab')2 fragments can thus be
achieved by chemical modification of copper chelates.
However, when the therapeutic efficacy of intact 
67Cu-labelled chCE7 antibody was compared with that of
the 67Cu-DOTA-R1- F(ab')2 fragment by calculating the
accumulated dose (AUC) in tumour and normal tissues
from an extended time course of biodistributions, the in-
tact antibody still achieved better therapeutic ratios than
the F(ab')2 fragment (Table 3). The data indicate that in-
tact 67Cu-labelled antibodies maximise tumour uptake
and therefore achieve better therapeutic ratios and that
they are at present the logical choice for clinical studies. 
Comparison with 64Cu-labelled antibodies
In contrast to the 67Cu nuclide, 64Cu, a PET nuclide, can
be produced with high specific activity, for instance by
irradiation of 64Ni targets with low-energy proton cur-
rents [41]. In addition to its emissions of β+ radiation
used for imaging, 64Cu also emits therapeutic β– parti-
cles. Its physical characteristics of quite different from
those of 67Cu, and include higher (therapeutically use-
less) γ energies and a shorter half-life (12.7 h) (see Ta-
ble 1). In addition to their application in PET imaging,
64Cu-labelled antibodies and peptides show therapeutic
effects in animal tumour models [42, 43] and they could
be potential agents for nuclide therapy. Although no clin-
ical data relating to the administration of therapeutic
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Table 2. Biodistribution of 67Cu-labelled fragments of mAb chCE7 in nude mice bearing neuroblastoma xenografts. DOTA-R1 is the tri-
glycine-linked chelate shown in Fig. 2D. (Data from Carrel et al. [38] and Zimmermann et al. [22])
Tissue 67Cu-CPTA-chCE7 67Cu-CPTA-chCE7 67Cu-DOTA-R1-chCE7 67Cu-DOTA-R1-chCE7 
Fab' F(ab')2 F(ab')2 F(ab')2
8 h p.i. 8 h p.i 8 h p.i 48 h p.i
Tumour 1.38±0.24 9.03±1.7 13.9±3.3 16.6±2.6
Blood 0.46±0.12 0.70±0.12 12.9±1.0 1.8±0.1
Kidney 138±41 100.3±10 15.9±1.3 10.9±1.2
Liver 3.73±0.52 6.4±2.8 10.6±0.9 10.1±0.4
Table 3. Cumulative retention of radioactivity (AUC) in tumour
and tissues of neuroblastoma-bearing nude mice: comparison of
67Cu-DOTA-R1-chCE7 F(ab')2 fragments with intact 67Cu-CPTA-
chCE7 antibody. (From Zimmermann et al. [22])
Tissue 67Cu-DOTA-R1-chCE7 67Cu-CPTA-chCE7
F(ab')2
AUC AUC ratio AUC AUC ratio
Tumour 1,716 – 5,460 –
Blood 466 3.7 599 9.1
Kidney 1,478 1.2 1,783 3.1
Liver 1,408 1.2 950 5.7
amounts of 64Cu-labelled radiopharmaceuticals have ap-
peared so far, in the case of radiocopper-labelled intact
antibodies (67/64Cu-2IT-BAT-Lym1), quantitative imag-
ing and estimates of radiation dosimetry indicate that the
67Cu-labelled antibody has a therapeutic advantage over
the 64Cu-labelled antibody in patients [44]. This is due to
the more favourable energy deposition of the 67Cu nu-
clide, with its smaller contribution from penetrating γ-ra-
diation, and to the longer half-life of 67Cu, which is more
compatible with the relatively slow pharmacokinetics of
antibodies. In the case of receptor binding peptides with
rapid pharmacokinetics, such as octreotide, which has
been evaluated as 64Cu-TETA-octreotide for imaging of
neuroendocrine tumours [45], the situation may be dif-
ferent, and a direct comparison of 67Cu with the 64Cu nu-
clide concerning both imaging/dosimetry and therapeutic
efficacy would be of particular interest.
Clinical studies with 67Cu-labelled antibodies
Targetting of non-Hodgkin’s lymphoma 
with 67Cu-2IT-BAT-Lym-1
Clinical studies with 67Cu-labelled antibodies were pio-
neered by the groups of S.J. and G.L. DeNardo at the
University of California Davis Medical Center [33, 46,
47, 48]. Their clinical target was non-Hodgkin’s lympho-
ma (NHL). They were able to show that RAIT with 131I-
labelled anti-lymphoma Lym-1 antibody is successful in
inducing therapeutic responses and prolonged survival
[49]. In order to evaluate 67Cu, with its better physical
characteristics, as a replacement for 131I, a 67Cu-TETA-
labelled Lym-1 radiopharmaceutical (67Cu-2IT-BAT-
Lym-1) was developed. Labelling protocols were optimi-
sed for specific activity to reduce the amount of antibody
per dose [24]. When immunological responses were
monitored after repeated administrations of therapeutic
amounts of the 67Cu-mAb (40–70 mg of Lym-1 antibody
with 125–267 µg of TETA conjugated to the antibody),
HAMA were detected in some instances (Lym-1 is a
mouse monoclonal antibody) but no antibodies against
the TETA chelating moiety were found [50]. The results
indicated that human antibody responses are not limiting
for the repeated applications necessary in fractionated
therapy. In a pilot study in three patients with advanced
B-lymphocyte NHL, an imaging dose of 370 MBq
(10 mCi) of 67Cu-2IT-BAT-Lym-1 was applied, followed
by a maximum of four therapy doses of 2.2 GBq
(60 mCi) of the 67Cu-antibody at intervals of 4 weeks
[33]. Good tumour imaging, favourable radiation dosim-
etry and a high therapeutic index (tumour to bone mar-
row radiation doses) were found. The maximum tolerat-
ed dose (MTD) for each of the first two doses was
2.2 GBq/m2, haematological toxicity being the dose-lim-
iting factor. In a subsequent clinical trial with 12 NHL
patients, a response rate of 58% was found [48]. Sequen-
tial application of 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1
was performed in four patients to evaluate 131I- and
67Cu-antibody in terms of their pharmacokinetics and do-
simetry, and it was found that 67Cu-2IT-BAT-Lym-1
showed higher tumour uptake and a longer residence
time in the tumour than 131I-Lym-1. Doses to normal or-
gans were similar for the two radiopharmaceuticals, with
the exception of the liver, where 67Cu-2IT-BAT-Lym-1
led to a higher dose [47]. The results obtained so far in-
dicate that 67Cu-2IT-BAT-Lym-1 is a safe and effective
reagent for RAIT and delivers higher doses to tumour
than 131I-Lym-1. It is clear that a larger number of pa-
tients will have to be treated in order to confirm that,
compared with 131I-Lym-1, 67Cu-2IT-BAT-Lym-1 yields
better therapeutic responses or cure.
Targetting of colon carcinoma with 67Cu-CPTA-mAb35
In patients with colorectal tumours, RAIT is believed to
be a valuable option in the presence of limited disease
and/or in an adjuvant setting with chemotherapy [51].
A study in six patients was performed at the Universi-
ty Hospital in Lausanne, Switzerland, comparing the bio-
distribution of 67Cu-CPTA- and 125I-labelled anti-CEA
antibody mAb35 [52]. Patients were scheduled for sur-
gery of primary colorectal cancer. Prior to surgery
185 MBq (5 mCi) of 67Cu-CPTA-mAb35 was co-inject-
ed together with 8.9 MBq (0.24 mCi) of 125I-mAb35.
Whole-body scanning and single-photon emission to-
mography were performed 1 h, 1 day and 2 days after in-
jection. Surgery was performed 2–8 days post injection,
and radioactivity in samples of tumour, normal colonic
mucosa, fat and blood was measured. The study con-
firmed preclinical data in nude mice bearing human co-
lon carcinoma xenografts, which showed higher tumour
uptake and more favourable tumour to blood ratio with
67Cu-mAb35 compared with 1311-mAb35 [28]. However,
liver uptake was noticeably higher in patients than in the
animal model. It was concluded that the possibilities of
achieving tumour response or cure are severely limited
in solid tumours, such as colon carcinoma, regardless of
whether 131I- or 67Cu-labelled antibodies are used. This
is also supported by observations in various clinical
RAIT trials of solid tumours, where the low radiation
doses delivered by RAIT are less effective than in the
case of lymphomas, which show therapeutic responses
even at low tumour doses.
Targetting of bladder cancer with 67Cu-CPTA-C595
The best results in RAIT of solid tumours have been ob-
tained through locoregional administration of radiola-
belled antibodies after reduction of the tumour burden by
surgery and radiation. Response rates of more than 50%
and prolonged survival have been achieved following in-
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tralesional application of 131I- or 90Y-labelled anti-tenas-
cin antibodies in malignant glioma [53] and intraperito-
neal application of 90Y- or 177Lu-labelled antibodies
against ovarian cancer [54, 55].
In the case of superficial bladder cancer, more effec-
tive locoregional therapies are being sought in order to
limit recurrence and progression. The majority of blad-
der cancer patients suffer from superficial disease con-
fined to the mucosa, and after endoscopic resection there
is a high incidence of recurrent disease. Treatment by in-
travesical chemotherapy has so far shown limited effica-
cy and significant side-effects. Intravesical application of
radiolabelled tumour-specific monoclonal antibodies
may be a more effective modality, targetting cytotoxic
radiation selectively to tumour tissue. The C595 mono-
clonal antibody recognises a peptide epitope in the
MUC1 mucin, a glycoprotein which is up-regulated on
malignant bladder urothelium. Localisation of bladder
tumour after intravesical application of 111In-labelled
C595 was demonstrated in the mid 1990s [56]. Subse-
quently, pilot studies were performed on cystectomy pa-
tients, in which bladders were infused ex vivo with 
67Cu-CPTA-C595 via a catheter immediately after sur-
gery. After incubation for 1 h, unbound antibody was
washed out and the bladder was imaged with a gamma
camera. Ex vivo imaging demonstrated antibody local-
isation corresponding to the sites of the tumour as con-
firmed histologically [27]. A diagnostic study with 16
patients diagnosed with superficial bladder cancer fol-
lowed [57]. 67Cu-CPTA-C595 (approximately 20 MBq)
was instilled in the bladder and after 1 h the bladder was
drained and irrigated. Both imaging and tissue counting
of tumour and normal tissues obtained by endoscopic re-
section was performed and showed successful imaging
in 12 out of 15 patients; an example is shown in Fig. 3.
A mean tumour to normal tissue ratio of 15:1 was found,
with large variations among patients (there is high varia-
tion in MUC1 expression in different tumours). When
serum levels of radioactivity were analysed after instilla-
tion of 67Cu-C595 into the bladder, no increase was
found, indicating that the activity remains enclosed in
the bladder. These results obtained by the groups at the
City Hospital and at the University Hospital in Notting-
ham (UK) indicate that 67Cu-C595 holds significant po-
tential for local therapy of bladder cancer, and a phase
I/II trial with doses up to 1.0 GBq is underway.
Conclusions and prospects
Based on the good results of preclinical and clinical
evaluations of 67Cu-labelled antibodies, broader clinical
investigations in radioimmunotherapy trials are desir-
able. The availability of the 67Cu nuclide is a limiting
factor for its more widespread use. Efforts to develop ef-
ficient procedures to produce large amounts of 67Cu with
high specific activity would significantly help the cause
of this interesting nuclide.
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